2017
DOI: 10.1111/ans.14312
|View full text |Cite
|
Sign up to set email alerts
|

Serial lipase for pancreatitis: not enough evidence

Abstract: The evidence supporting or opposing serial lipase as a prognostic factor for pancreatitis is weak and consists mainly of retrospective analyses. The only prospective data identified suggested benefits to serial lipase in prognosis. Further prospective studies evaluating the prognostic value of serial lipase in the adult population with both traumatic and non-traumatic pancreatitis are required given the paucity of available evidence.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 37 publications
0
3
0
Order By: Relevance
“…An important feature of the case was the direct correlation between serum pancreatic enzyme levels and regression of the panniculitis (see figure 5). Serial lipase and amylase levels were not initially part of the management plan, a conscious decision by the treating team guided by the paucity of evidence for serial testing of pancreatic enzymes in the management of pancreatitis—an unnecessary cost to the healthcare system with no appreciable impact on prognosis or outcome 13 14. However, for patients presenting with pancreatic panniculitis, serial testing of serum pancreatic enzymes appears useful in identifying potential drivers behind the ongoing panniculitis—levels which in this case remained elevated despite 2 weeks of standard acute pancreatitis management and both clinical and radiological resolution of the pancreatitis.…”
Section: Discussionmentioning
confidence: 95%
“…An important feature of the case was the direct correlation between serum pancreatic enzyme levels and regression of the panniculitis (see figure 5). Serial lipase and amylase levels were not initially part of the management plan, a conscious decision by the treating team guided by the paucity of evidence for serial testing of pancreatic enzymes in the management of pancreatitis—an unnecessary cost to the healthcare system with no appreciable impact on prognosis or outcome 13 14. However, for patients presenting with pancreatic panniculitis, serial testing of serum pancreatic enzymes appears useful in identifying potential drivers behind the ongoing panniculitis—levels which in this case remained elevated despite 2 weeks of standard acute pancreatitis management and both clinical and radiological resolution of the pancreatitis.…”
Section: Discussionmentioning
confidence: 95%
“…It has been reported that ANC and its complications account for 70–86% of mortality of patients with pancreatitis, and the prognosis is very poor [20]. Some studies have reported that ANC can cause severe inflammatory reactions around the pancreas, resulting in morphological and functional damage to the pancreas, decreased levels of secreted pancreatic enzymes, and poor digestion of lipids, which may be one of the reasons for RAP [21]. In addition, the long-term inflammatory reaction can cause pancreatic necrosis, which is not accurately identified by CT in the early stage, resulting in rapid recurrence after conservative treatment [22,23].…”
Section: Discussionmentioning
confidence: 99%
“…8 The evidence for utilizing lipase as a prognostic marker is weak, and far stronger risk-stratifi cation tools exist. [7][8][9] ■ SYMPTOMS AND CLINICAL CRITERIA SHOULD GUIDE MANAGEMENT Symptom-guided and clinical criteria-guided management are the standard of care in acute pancreatitis to facilitate clinical decisions. The use of lipase, a diagnostic test, should not supersede clinical judgment.…”
Section: Qmentioning
confidence: 99%